pharma · MPS IIIA · Epidermolysis Bullosa · ABEO
ABEONA THERAPEUTICS
ABEONA THERAPEUTICS INC.
ABEONA THERAPEUTICS clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Cleveland, USA
- Founded
- 2015
- Employees
- 228
- Programs
- 8
- Drugs
- 3
- Patents
- 0
ABEONA THERAPEUTICS projects
8 ClinicalTrials.gov programs sponsored by ABEONA THERAPEUTICS.
ABEONA THERAPEUTICS has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
EB-101
ABEONA THERAPEUTICS INC.
Epidermolysis Bullosa
1 trial -
EB-101 Surgical application of RDEB wounds
ABEONA THERAPEUTICS INC.
Epidermolysis Bullosa
1 trial -
UX111
ABEONA THERAPEUTICS INC.
MPS IIIA
1 trial -
ofloxacin
ABEONA THERAPEUTICS INC.
Diabetic Foot Ulcers
2 trials -
ABO-102
ABEONA THERAPEUTICS INC.
MPS IIIA
1 trial -
EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
ABEONA THERAPEUTICS INC.
Onychomycosis
1 trial -
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
ABEONA THERAPEUTICS INC.
Epidermolysis Bullosa Dystrophica
1 trial -
rAAV9.CMV.hNAGLU
ABEONA THERAPEUTICS INC.
Mucopolysaccharidosis Type 3 B
1 trial
Frequently asked questions
How many clinical projects does ABEONA THERAPEUTICS have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.